| Bioactivity | BMS-748730 is an oral tyrosine kinase inhibitor. BMS-748730 inhibits tyrosine kinase activity by competing with the ATP binding site of the tyrosine kinase, which prevents the kinase from phosphorylating the substrate protein, thereby inhibiting signaling pathways associated with cell proliferation and tumor growth. BMS-748730 can be used in the study of certain types of cancer, including chronic myeloid leukemia (CML)[1]. |
| CAS | 910297-57-3 |
| Formula | C22H26ClN7O3S |
| Molar Mass | 504.00 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Erp, P. H. van. Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. Leiden University Medical Center (LUMC), Leiden University. 2009, December 16. |
BMS-748730
CAS: 910297-57-3 F: C22H26ClN7O3S W: 504.00
BMS-748730 is an oral tyrosine kinase inhibitor. BMS-748730 inhibits tyrosine kinase activity by competing with the ATP
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.